QQQ   280.53 (-0.41%)
AAPL   140.94 (-1.38%)
MSFT   244.37 (-0.31%)
META   113.93 (-0.17%)
GOOGL   94.94 (-2.10%)
AMZN   88.46 (+0.24%)
TSLA   174.04 (-3.21%)
NVDA   161.20 (+0.83%)
NIO   12.58 (-4.98%)
BABA   88.33 (-3.41%)
AMD   70.14 (-0.19%)
T   19.30 (+0.68%)
MU   53.82 (+0.26%)
CGC   3.24 (-10.25%)
F   13.10 (-1.36%)
GE   85.00 (-0.33%)
DIS   92.15 (-0.15%)
AMC   6.05 (-10.37%)
PYPL   74.42 (+3.03%)
PFE   50.24 (+1.07%)
NFLX   308.42 (+0.94%)
QQQ   280.53 (-0.41%)
AAPL   140.94 (-1.38%)
MSFT   244.37 (-0.31%)
META   113.93 (-0.17%)
GOOGL   94.94 (-2.10%)
AMZN   88.46 (+0.24%)
TSLA   174.04 (-3.21%)
NVDA   161.20 (+0.83%)
NIO   12.58 (-4.98%)
BABA   88.33 (-3.41%)
AMD   70.14 (-0.19%)
T   19.30 (+0.68%)
MU   53.82 (+0.26%)
CGC   3.24 (-10.25%)
F   13.10 (-1.36%)
GE   85.00 (-0.33%)
DIS   92.15 (-0.15%)
AMC   6.05 (-10.37%)
PYPL   74.42 (+3.03%)
PFE   50.24 (+1.07%)
NFLX   308.42 (+0.94%)
QQQ   280.53 (-0.41%)
AAPL   140.94 (-1.38%)
MSFT   244.37 (-0.31%)
META   113.93 (-0.17%)
GOOGL   94.94 (-2.10%)
AMZN   88.46 (+0.24%)
TSLA   174.04 (-3.21%)
NVDA   161.20 (+0.83%)
NIO   12.58 (-4.98%)
BABA   88.33 (-3.41%)
AMD   70.14 (-0.19%)
T   19.30 (+0.68%)
MU   53.82 (+0.26%)
CGC   3.24 (-10.25%)
F   13.10 (-1.36%)
GE   85.00 (-0.33%)
DIS   92.15 (-0.15%)
AMC   6.05 (-10.37%)
PYPL   74.42 (+3.03%)
PFE   50.24 (+1.07%)
NFLX   308.42 (+0.94%)
QQQ   280.53 (-0.41%)
AAPL   140.94 (-1.38%)
MSFT   244.37 (-0.31%)
META   113.93 (-0.17%)
GOOGL   94.94 (-2.10%)
AMZN   88.46 (+0.24%)
TSLA   174.04 (-3.21%)
NVDA   161.20 (+0.83%)
NIO   12.58 (-4.98%)
BABA   88.33 (-3.41%)
AMD   70.14 (-0.19%)
T   19.30 (+0.68%)
MU   53.82 (+0.26%)
CGC   3.24 (-10.25%)
F   13.10 (-1.36%)
GE   85.00 (-0.33%)
DIS   92.15 (-0.15%)
AMC   6.05 (-10.37%)
PYPL   74.42 (+3.03%)
PFE   50.24 (+1.07%)
NFLX   308.42 (+0.94%)
NASDAQ:PRVB

Provention Bio - PRVB Stock Forecast, Price & News

$9.13
+0.20 (+2.24%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.82
$9.14
50-Day Range
$4.43
$9.50
52-Week Range
$3.18
$9.85
Volume
775,175 shs
Average Volume
1.09 million shs
Market Capitalization
$796.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.40

Provention Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
134.4% Upside
$21.40 Price Target
Short Interest
Bearish
6.85% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.90
Upright™ Environmental Score
News Sentiment
0.87mentions of Provention Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.66) to ($1.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

366th out of 1,027 stocks

Pharmaceutical Preparations Industry

155th out of 503 stocks

PRVB stock logo

About Provention Bio (NASDAQ:PRVB) Stock

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

PRVB Stock News Headlines

Why Shares of Provention Bio Went Up 30.3% in November
Provention Bio (NASDAQ:PRVB) Stock Price Down 3.7%
What 5 Analyst Ratings Have To Say About Provention Bio
Provention Bio (PRVB) Stock Falls Despite FDA Approval
Provention Bio diabetes drug to cost $13,850/vial
Why Is Provention Biosciences (PRVB) Stock Up 25% Today?
Provention Bio: Q3 Earnings Insights
These 2 Growth Stocks Have Potential Catalysts on the Way
Why Provention Bio Shares Are Skyrocketing Today
1 Green Flag and 1 Red Flag for Provention Bio
Provention Bio Announces Senior Leadership Addition
See More Headlines
Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

PRVB Company Calendar

Last Earnings
11/04/2021
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRVB
Fax
N/A
Employees
82
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.40
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+134.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-114,430,000.00
Net Margins
-3,791.21%
Pretax Margin
-4,043.30%

Debt

Sales & Book Value

Annual Sales
$1.39 million
Book Value
$1.75 per share

Miscellaneous

Free Float
75,769,000
Market Cap
$796.05 million
Optionable
Not Optionable
Beta
2.40

Key Executives

  • Mr. Ashleigh W. Palmer B.Sc.Mr. Ashleigh W. Palmer B.Sc. (Age 59)
    M.B.A., Co-Founder, Pres, CEO & Director
    Comp: $900.3k
  • Mr. Thierry Chauche (Age 46)
    Chief Financial Officer
    Comp: $411.37k
  • Dr. Eleanor L. Ramos M.D. (Age 66)
    Chief Medical Officer
    Comp: $611.72k
  • Dr. Francisco  Leon M.D.Dr. Francisco Leon M.D. (Age 50)
    Ph.D., Co-Founder & Chief Scientific Officer
  • Ms. Christina Yi (Age 46)
    Chief Operations Officer
  • Mr. Robert A. Doody Jr.
    VP of Investor Relations
  • Ms. Heidy Abreu King-Jones J.D. (Age 39)
    L.L.M., Chief Legal Officer
  • Kaelan Hollon
    VP of Corp. Communications
  • Mr. Jason Levine
    VP Marketing
  • Sarah O'Brien
    Chief People Officer













PRVB Stock - Frequently Asked Questions

Should I buy or sell Provention Bio stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRVB shares.
View PRVB analyst ratings
or view top-rated stocks.

What is Provention Bio's stock price forecast for 2023?

6 Wall Street analysts have issued 12 month price targets for Provention Bio's shares. Their PRVB share price forecasts range from $18.00 to $30.00. On average, they predict the company's stock price to reach $21.40 in the next twelve months. This suggests a possible upside of 134.4% from the stock's current price.
View analysts price targets for PRVB
or view top-rated stocks among Wall Street analysts.

How have PRVB shares performed in 2022?

Provention Bio's stock was trading at $5.62 at the start of the year. Since then, PRVB stock has increased by 62.5% and is now trading at $9.13.
View the best growth stocks for 2022 here
.

When is Provention Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our PRVB earnings forecast
.

How were Provention Bio's earnings last quarter?

Provention Bio, Inc. (NASDAQ:PRVB) released its quarterly earnings results on Thursday, November, 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.08. The company had revenue of $0.68 million for the quarter, compared to the consensus estimate of $3.75 million. Provention Bio had a negative net margin of 3,791.21% and a negative trailing twelve-month return on equity of 99.08%. During the same quarter last year, the firm posted ($0.56) EPS.

What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV).

What is Provention Bio's stock symbol?

Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."

Who are Provention Bio's major shareholders?

Provention Bio's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.77%), Vanguard Group Inc. (4.13%), State Street Corp (1.48%), Verition Fund Management LLC (0.99%), Bioimpact Capital LLC (0.85%) and Palo Alto Investors LP (0.45%). Insiders that own company stock include Andrew T Drechsler, Ashleigh Palmer, Eleanor Ramos, Francisco Leon and Jason Hoitt.
View institutional ownership trends
.

How do I buy shares of Provention Bio?

Shares of PRVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Provention Bio's stock price today?

One share of PRVB stock can currently be purchased for approximately $9.13.

How much money does Provention Bio make?

Provention Bio (NASDAQ:PRVB) has a market capitalization of $796.05 million and generates $1.39 million in revenue each year. The company earns $-114,430,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

How can I contact Provention Bio?

Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The official website for the company is www.proventionbio.com. The company can be reached via phone at (908) 428-9136 or via email at kimberly@argotpartners.com.

This page (NASDAQ:PRVB) was last updated on 12/7/2022 by MarketBeat.com Staff